Zurcher Kantonalbank Zurich Cantonalbank Acquires 8,390 Shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH)

Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) by 24.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 42,641 shares of the biotechnology company’s stock after purchasing an additional 8,390 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Aurinia Pharmaceuticals were worth $343,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently modified their holdings of the company. GF Fund Management CO. LTD. purchased a new position in shares of Aurinia Pharmaceuticals in the 4th quarter worth about $27,000. Tower Research Capital LLC TRC raised its position in shares of Aurinia Pharmaceuticals by 368.5% in the 4th quarter. Tower Research Capital LLC TRC now owns 3,350 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 2,635 shares during the last quarter. Vermillion & White Wealth Management Group LLC purchased a new position in shares of Aurinia Pharmaceuticals in the 4th quarter worth about $31,000. GAMMA Investing LLC raised its position in shares of Aurinia Pharmaceuticals by 56.1% in the 1st quarter. GAMMA Investing LLC now owns 4,852 shares of the biotechnology company’s stock worth $39,000 after purchasing an additional 1,744 shares during the last quarter. Finally, Natixis purchased a new position in shares of Aurinia Pharmaceuticals in the 4th quarter worth about $49,000. Hedge funds and other institutional investors own 36.83% of the company’s stock.

Insiders Place Their Bets

In other Aurinia Pharmaceuticals news, Director Kevin Tang bought 1,000,000 shares of the firm’s stock in a transaction on Friday, August 1st. The stock was acquired at an average price of $10.12 per share, with a total value of $10,120,000.00. Following the transaction, the director owned 11,029,500 shares in the company, valued at $111,618,540. This represents a 9.97% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Over the last ninety days, insiders bought 1,300,000 shares of company stock valued at $13,590,000. 12.20% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on AUPH shares. Royal Bank Of Canada lifted their price target on Aurinia Pharmaceuticals from $8.00 to $9.00 and gave the stock an “outperform” rating in a research report on Friday, August 1st. HC Wainwright reaffirmed a “buy” rating and issued a $17.00 price target on shares of Aurinia Pharmaceuticals in a research report on Wednesday, July 30th.

Aurinia Pharmaceuticals Price Performance

Shares of NASDAQ:AUPH opened at $11.37 on Friday. Aurinia Pharmaceuticals Inc has a fifty-two week low of $5.29 and a fifty-two week high of $11.80. The business has a 50-day simple moving average of $8.70 and a two-hundred day simple moving average of $8.26. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.63 and a current ratio of 5.23. The firm has a market cap of $1.50 billion, a price-to-earnings ratio of 26.44 and a beta of 1.23.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last issued its earnings results on Thursday, July 31st. The biotechnology company reported $0.16 earnings per share for the quarter, missing analysts’ consensus estimates of $0.17 by ($0.01). Aurinia Pharmaceuticals had a return on equity of 20.06% and a net margin of 23.31%. The business had revenue of $70.01 million during the quarter, compared to analysts’ expectations of $64.27 million. On average, analysts expect that Aurinia Pharmaceuticals Inc will post 0.11 earnings per share for the current year.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.